Exicure, Inc. (NASDAQ:XCUR – Get Free Report) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 125,400 shares, a decline of 22.5% from the June 30th total of 161,800 shares. Based on an average daily volume of 566,900 shares, the short-interest ratio is presently 0.2 days. Currently, 2.8% of the company’s shares are sold short.
Exicure Stock Performance
NASDAQ:XCUR opened at $0.48 on Monday. The stock’s 50-day moving average is $0.37 and its 200-day moving average is $0.52. Exicure has a 1-year low of $0.29 and a 1-year high of $1.14.
Exicure (NASDAQ:XCUR – Get Free Report) last announced its earnings results on Thursday, June 6th. The company reported ($0.13) EPS for the quarter.
Exicure Company Profile
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Further Reading
- Five stocks we like better than Exicure
- Are Penny Stocks a Good Fit for Your Portfolio?
- Verizon Stock: 4 Reasons to Buy This Bargain After Recent Dip
- The How And Why of Investing in Oil Stocks
- Why a Weaker Dollar is Good News for These 3 Stocks
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Why Bank of America Just Approved a Huge Stock Buyback Program
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
